Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company’s Genetic Diagnostic for Addiction Treatment

Barchart · 10/17 08:00

GLEN ALLEN, Va., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that the United States Patent and Trademark Office has issued a Notice of Allowance for a new patent.

Read more at globenewswire.com